This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—Dr Green has presented a very cogent exposé of a troubling cancer therapy of unknown efficacy.Green analyzes in exquisite detail the biochemical and experimental results associated with antineoplastons, which would raise questions about their use in any clinical setting. It is one thing for new drugs under development to be studied in a classic phase I study, having gone through preclinical trials and deemed valid to merit clinical study after careful peer review. This apparently is not the case in the antineoplaston story, which raises serious concerns as to how this type of activity is allowed to continue.I have had personal experience with one patient, a 38-year-old woman, who developed recurrent rectal cancer involving the lower pelvis. This patient's cancer had progressed in spite of treatment with radiation and chemotherapy and was looking for alternative therapy. She found her way to the Burzynski Clinic where
Wanebo HJ. Antineoplastons: The Controversy Continues. JAMA. 1993;269(4):476. doi:10.1001/jama.1993.03500040041029